KR20150031322A - 사이토메갈로바이러스 단백질의 복합체 - Google Patents

사이토메갈로바이러스 단백질의 복합체 Download PDF

Info

Publication number
KR20150031322A
KR20150031322A KR1020157002267A KR20157002267A KR20150031322A KR 20150031322 A KR20150031322 A KR 20150031322A KR 1020157002267 A KR1020157002267 A KR 1020157002267A KR 20157002267 A KR20157002267 A KR 20157002267A KR 20150031322 A KR20150031322 A KR 20150031322A
Authority
KR
South Korea
Prior art keywords
leu
thr
ser
val
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157002267A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 카르피
잉시아 웬
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48783208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150031322(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150031322A publication Critical patent/KR20150031322A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/045—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157002267A 2012-07-06 2013-06-29 사이토메갈로바이러스 단백질의 복합체 Withdrawn KR20150031322A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261668975P 2012-07-06 2012-07-06
US61/668,975 2012-07-06
US201361770257P 2013-02-27 2013-02-27
US61/770,257 2013-02-27
PCT/EP2013/063750 WO2014005959A1 (en) 2012-07-06 2013-06-29 Complexes of cytomegalovirus proteins

Publications (1)

Publication Number Publication Date
KR20150031322A true KR20150031322A (ko) 2015-03-23

Family

ID=48783208

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157002267A Withdrawn KR20150031322A (ko) 2012-07-06 2013-06-29 사이토메갈로바이러스 단백질의 복합체

Country Status (17)

Country Link
US (4) US9683022B2 (https=)
EP (1) EP2869843B1 (https=)
JP (3) JP2015522581A (https=)
KR (1) KR20150031322A (https=)
CN (1) CN104853771A (https=)
AU (1) AU2013286093B2 (https=)
CA (1) CA2878344A1 (https=)
ES (1) ES2753138T3 (https=)
GB (1) GB2513768B (https=)
HK (1) HK1210037A1 (https=)
IL (1) IL236261A0 (https=)
IN (1) IN2014KN02929A (https=)
MX (2) MX355469B (https=)
RU (1) RU2015103891A (https=)
SG (1) SG11201408328VA (https=)
WO (1) WO2014005959A1 (https=)
ZA (1) ZA201409364B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250048132A (ko) * 2020-06-09 2025-04-07 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CN110241137A (zh) 2012-07-27 2019-09-17 希望之城 一种递送ul128复合体和预防cmv感染的mva疫苗
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP6818551B2 (ja) * 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
WO2015165480A1 (en) * 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
AU2015251221A1 (en) * 2014-04-23 2016-10-27 CARIPLO, Fondazione Human cytomegalovirus vaccine compositions and method of producing the same
MX2016014660A (es) * 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
EP3047856A1 (en) * 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
WO2017044895A2 (en) 2015-09-10 2017-03-16 City Of Hope MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
BR112018014109A2 (en) 2016-01-11 2018-12-11 Verndari, Inc. microneedle compositions and methods of using them
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3528821A4 (en) 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US11572389B2 (en) * 2017-01-27 2023-02-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11174322B2 (en) * 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
CN111163799A (zh) 2017-07-28 2020-05-15 扬森疫苗与预防公司 用于异源repRNA免疫接种的方法和组合物
US11524069B2 (en) * 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN112638411B (zh) 2018-05-04 2025-03-04 斯拜生物技术有限公司 疫苗组合物
CN113271968B (zh) * 2018-10-17 2024-06-14 葛兰素史密丝克莱恩生物有限公司 经修饰的巨细胞病毒蛋白和稳定化的复合物
CA3121915C (en) 2018-12-10 2025-05-20 Km Biologics Co., Ltd. VACCINE FOR THE PREVENTION OR TREATMENT OF CONGENITAL CYTOMEGALOVIRUS INFECTION
US11629172B2 (en) * 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
AU2021367917A1 (en) 2020-10-28 2023-06-22 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
CA3211449A1 (en) * 2021-02-24 2022-09-01 Pfizer Inc. Novel druggable regions in the human cytomegalovirus glycoprotein b polypeptide and methods of use thereof
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006953A2 (en) 1988-12-22 1990-06-28 Genentech, Inc. Method for preparing water soluble polypeptides
EP0388186A1 (en) 1989-03-17 1990-09-19 E.I. Du Pont De Nemours And Company External regulation of gene expression
WO1992002628A1 (en) 1990-08-02 1992-02-20 Chiron Corporation Expression of human cmv glycoprotein-h using the baculovirus-insect cell expression system
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US5815900A (en) 1995-03-06 1998-10-06 Matsushita Electric Industrial Co., Ltd. Method of manufacturing a surface acoustic wave module
US20040228842A1 (en) * 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US7947274B2 (en) * 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
WO2011106607A2 (en) * 2010-02-26 2011-09-01 Juvaris Biotherapeutics, Inc. Subunit vaccines for herpes viruses and methods of use
ES2557382T3 (es) 2010-07-06 2016-01-25 Glaxosmithkline Biologicals Sa Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
WO2012015211A2 (ko) 2010-07-30 2012-02-02 주식회사종근당 사이클로스포린 에이 함유 점안제 조성물
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
WO2012051211A2 (en) 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
EA033467B1 (ru) * 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
MX350258B (es) * 2011-07-06 2017-08-31 Novartis Ag Emulsiones cationicas de aceite en agua.
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
MX366055B (es) * 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250048132A (ko) * 2020-06-09 2025-04-07 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신
US12569552B2 (en) 2020-06-09 2026-03-10 Km Biologics Co., Ltd. Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein

Also Published As

Publication number Publication date
MX355469B (es) 2018-04-19
GB2513768B (en) 2015-04-15
US9683022B2 (en) 2017-06-20
US20160159864A1 (en) 2016-06-09
IN2014KN02929A (https=) 2015-05-08
US20170320916A1 (en) 2017-11-09
WO2014005959A1 (en) 2014-01-09
SG11201408328VA (en) 2015-02-27
ES2753138T3 (es) 2020-04-07
EP2869843A1 (en) 2015-05-13
US10287322B2 (en) 2019-05-14
JP2015522581A (ja) 2015-08-06
JP2017192399A (ja) 2017-10-26
RU2015103891A (ru) 2016-08-27
CN104853771A (zh) 2015-08-19
US20190211064A1 (en) 2019-07-11
CA2878344A1 (en) 2014-01-09
EP2869843B1 (en) 2019-08-07
MX2014015496A (es) 2015-03-06
MX378747B (es) 2025-03-10
GB2513768A (en) 2014-11-05
GB201413863D0 (en) 2014-09-17
AU2013286093B2 (en) 2018-01-04
US20220106364A1 (en) 2022-04-07
JP2017192400A (ja) 2017-10-26
HK1210037A1 (en) 2016-04-15
ZA201409364B (en) 2017-08-30
AU2013286093A1 (en) 2015-02-12
IL236261A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
AU2013286093B2 (en) Complexes of cytomegalovirus proteins
KR102242990B1 (ko) 헤테로다이머 면역글로불린 구조체 및 이의 제조 방법
CN110023500B (zh) 作为选择标记的减毒谷氨酰胺合成酶
KR20140095556A (ko) 사이토메갈로바이러스의 치료를 위한 조성물 및 방법
KR20090078353A (ko) Ｌｉｎｇｏ 결합 분자 및 그의 제약학적 용도
JP7684271B2 (ja) Ｔ細胞レセプター及びｔ細胞抗原の同定及び特徴決定のための遺伝子操作された多成分システム
KR20080031296A (ko) Ｐｓｍａ 항체-약물 접합체
AU2024200154A1 (en) An engineered multi-component system for identification and characterisation of T-cell receptors, T-cell antigens and their functional interaction
KR20230167100A (ko) 안구 트랜스진 발현을 위한 조성물 및 방법
CN102516396A (zh) 诱导可逆性永生化前成牙本质细胞系及其建立方法
KR20190042473A (ko) 중증 혈소판 감소 증후군 바이러스 예방 및 치료용 유전자 백신
CN110922484B (zh) 抗EGFRvIII抗体及其在疾病诊断或治疗中的应用
US20170283484A1 (en) Anti-hepatitis c antibodies and antigen binding fragments thereof
US20240263143A1 (en) Baby Hamster Kidney (BHK) Cells Transformed with the Adenoviral E1 Gene for Production of Recombinant Adeno-Associated Virus
KR20230034934A (ko) 바이러스-유사 입자를 생산하기 위한 벡터 및 그의 용도
CN109053903B (zh) 一种重组人CREG-Fc融合蛋白的制备及其应用
KR102956777B1 (ko) T-세포 수용체 및 t-세포 항원의 식별 및 특징규명을 위한 조작된 다성분 시스템
KR20240023127A (ko) 망막 장애
CN117813321A (zh) 视网膜病症
JP2000354490A (ja) シグナルペプチド

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid